Turning Cancer Friend Into Cancer Foe

Main Category: Cancer / Oncology
Also Included In: Biology / Biochemistry;  Genetics
Article Date: 08 Oct 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Burnham Institute for Medical Research has announced that scientists have created a peptide that binds to Bcl-2, a protein that protects cancer cells from programmed cell death, and converts it into a cancer cell killer. The research, which was published as the featured article in the October 7 edition of Cancer Cellmay lead to new cancer treatments.

The Bcl-2 protein has long been implicated in protecting cancer cells from apoptosis (programmed cell death), the process that usually keeps cancer cells in check. This peptide (called NuBCP-9) and its enantiomer (mirror-image molecule) work on Bcl-2 like a molecular switch, converting it into a pro-apoptotic protein, and inducing cell death in cancer cells.

"Our results provide insight into Bcl-2 conversion and identify a new direction for Bcl-2-based drug leads and cancer drug development," said Xiao-kun Zhang, Ph.D., who co-authored the paper with Arnold Satterthwait, Ph.D. and others.

The NuBCP-9 peptide was created from Nur77, a potent pro-apoptotic protein. Nur77 often moves from the nucleus to mitochondria, in response to different death signals, where it binds to Bcl-2, changing its shape and function.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

About Burnham Institute for Medical Research

Burnham Institute for Medical Research is dedicated to revealing the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Burnham is one of the fastest growing research institutes in the country with operations in California and Florida. The Institute ranks among the top four institutions nationally for NIH grant funding and among the top 25 organizations worldwide for its research impact. Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, infectious and inflammatory and childhood diseases. The Institute is known for its world-class capabilities in stem cell research and drug discovery technologies. Burnham is a nonprofit, public benefit corporation. For more information, please visit http://www.burnham.org/.

Source: Josh Baxt
Burnham Institute